Marshall Wace LLP Purchases Shares of 837,374 Alto Neuroscience, Inc. (NYSE:ANRO)

Marshall Wace LLP bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 837,374 shares of the company's stock, valued at approximately $3,542,000. Marshall Wace LLP owned about 3.10% of Alto Neuroscience as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the business. State Street Corp increased its holdings in Alto Neuroscience by 123.7% during the 3rd quarter. State Street Corp now owns 236,857 shares of the company's stock worth $2,710,000 after purchasing an additional 130,985 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience during the third quarter worth approximately $124,000. Barclays PLC increased its stake in shares of Alto Neuroscience by 872.7% in the third quarter. Barclays PLC now owns 29,599 shares of the company's stock worth $339,000 after buying an additional 26,556 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Alto Neuroscience by 148.7% in the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company's stock worth $5,378,000 after buying an additional 281,018 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock valued at $13,965,000 after acquiring an additional 595,673 shares in the last quarter.

Analyst Ratings Changes

ANRO has been the subject of several research analyst reports. HC Wainwright initiated coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They issued a "buy" rating and a $10.00 target price for the company. William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO traded down $0.06 during midday trading on Thursday, hitting $2.43. The company's stock had a trading volume of 28,687 shares, compared to its average volume of 377,584. The firm has a market cap of $65.78 million, a P/E ratio of -0.96 and a beta of 2.16. Alto Neuroscience, Inc. has a 1-year low of $1.60 and a 1-year high of $17.55. The firm's fifty day moving average price is $2.58 and its 200-day moving average price is $4.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.09. On average, sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.